1 |
<p align="center"><b>PLIVA's new drug forms and price changes on the new Reimbursement |
2 |
list of the Croatian Institute for Health Insurance</b></p> |
3 |
<p>Zagreb, 15 February 2000</p> |
4 |
<p>The Croatian Institute for Health Insurance has announced its reimbursment |
5 |
list as of 15 February 2000. This includes five new drug forms produced by PLIVA: |
6 |
Sumamed injections (azithromycin), 5 mg Cilazil tablets (cilazapril), Diflucan |
7 |
syrup (fluconazole), Kalorijska otopina LGX 24% and Kalorijska otopina LGX 40% |
8 |
(calorie solutions). These newest additions to PLIVA's product portfolio are |
9 |
expected to increase sales incrementally.</p> |
10 |
<p>The prices of about ten PLIVA products have also been adjusted. Among the leading |
11 |
products, Peptoran tablets (ranitidine) will now be available at a lower price, |
12 |
and Tonocardin (doxazosin) at a higher price. These price adjustments are expected |
13 |
to have a net effect of HRK -16 m. on PLIVA's revenue this year. </p> |